Doxycycline

Research use only, not for human use.

Doxycycline is a synthetic tetracycline derivative with similar antimicrobial activity.

Doxycycline is a synthetic tetracycline derivative with similar antimicrobial activity.

Doxycycline (0.01-10 μg/mL, 4 d) affects growth of glioma cells only under high concentrations.Doxycycline (0.01-10 μg/mL, 24 h) decreases MT-CO1 protein content with concentrations of 1 μg/mL and higher in SVG cells.Doxycycline (100 ng/mL, 1 μg/mL; 24 h) reduces proliferation of human cell lines.Doxycycline (0-250 μM, 72 h) inhibits cell viability of breast cancer cells . Cell Viability AssayCell Line:LNT-229, G55, and U343 glioma cells Concentration:0.01, 0.1, 1 or 10 μg/mL Incubation Time:4 days Result:Affected growth of glioma cells only under high concentration (10 μg/mL).Cell Viability Assay Cell Line:SVG cells Concentration:0.01, 0.1, 1 or 10 μg/mL Incubation Time:24 hours Result:Decreaseed MT-CO1 protein content with concentrations of 1 μg/mL and higher.Cell Proliferation Assay Cell Line:MCF 12A, 293T cells Concentration:100 ng/mL, 1 μg/mL Incubation Time:96 hours Result:Caused reduced proliferation of MCF 12A and 293T cells at 1 μg/mL.Cell Viability Assay Cell Line:MCF-7, MDA-MB-468 cells Concentration:0-250 μM Incubation Time:72 hours Result:Inhibited breast cancer cells in a dose-dependent manner with IC50 values for MCF-7 and MDA-MB-468 of 11.39 μM and 7.13 μM respectively.

Doxycycline (oral gavage; 200 or 800 mg/kg; once daily; 3 months) reduces MMP-9 activity in untreated HT mice in a dose-dependent manner.Doxycycline and Tetracycline (HY-A0107), act systemically after absorption from the upper gastrointestinal tract. The main advantage of Doxycycline over Tetracycline is its longer activity, and it can be taken twice or once a day. The peak concentration of both drugs is similar, but in the case of Doxycycline the time to peak concentration is shorter, and half life is significantly longer. Animal Model:6-month-old female Heterozygous Col3a1-deficient (HT) miceDosage:200 or 800 mg/kg Administration:Oral gavage; 200 or 800 mg/kg; once daily; 3 monthsResult:Reduced active MMP-9 in a dose-dependent manner.

——

Microbiology/Virology

ribosome

16S ribosome| 30S ribosome

——

——

564-25-0

444.44

C22H24N2O8

>98% (HPLC)

Water: 630 mg/L

O=C(C(C1=O)=C(O)[C@@H](N(C)C)[C@]2([H])[C@@H](O)[C@]3([H])[C@@H](C)C4=C(C(C3=C(O)[C@@]21O)=O)C(O)=CC=C4)N

2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, (4S,4aR,5S,5aR,6R,12aS)-

(-20℃)

With Ice Pack

≥ 2 years